Nouryon plans to invest in its Kromasil manufacturing facility in Sweden to double production capacity and meet global demand from pharmaceutical and biotech industries. The expansion will strengthen Nouryon's position in high-performance silica market. Construction is set to begin in 2022, following the success of Kromasil products in various industries.
Nouryon, a global specialty chemicals leader, plans to invest in its Kromasil manufacturing facility in Bohus, Sweden, to meet the increasing global demand from the pharmaceutical and biotechnology industries for high-performing solutions. The investment is expected to double the facility’s existing production capacity, which will strengthen Nouryon’s global leadership position in high-performance silica.
“This investment reflects Nouryon’s commitment to be a trusted partner to the pharma and biotech industries, which increasingly rely on us to provide solutions that contribute to the production of safe pharmaceuticals,” said Johan Landfors, Executive Vice President and President, Technology Solutions and Europe at Nouryon.
Kromasil products are used by the pharmaceutical, food and beverage, clinical, and environmental industries for applications ranging from laboratory analysis to industrial-scale purification. Kromasil contributes to improved treatment of diabetes as a vital part of the purification of insulin. Other uses include complex bio-pharma applications.
"Bio-pharmaceuticals, such as peptides, proteins and hormones, are a growing market and we see an increase in demand worldwide, particularly from our customers in India, China and Southeast Asia,” said Patrick Wilhelm, Vice President of Inorganic Specialties at Nouryon. “This facility expansion will reinforce our leadership position in the global high-performance silica market targeted to the pharma and biotech industries, and it will allow us to meet the growing demand for our Kromasil products.”
Construction of the Nouryon facility expansion is scheduled to begin in 2022.
Nouryon is a leading producer of high-performance silica worldwide and has more than 30 years of expertise in spherical silica for analytical to process-scale liquid chromatography under the brand Kromasil. Kromasil chromatography resins offer superior separation performance leading to increased efficiency and decreased costs.
This investment follows Kromasil’s recently introduced efficient purification strategy for pharmaceuticals used for type 2 diabetes.